Literature DB >> 17684010

Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling.

Henriette Bendz1, Sibylle C Ruhland, Maya J Pandya, Otmar Hainzl, Stefan Riegelsberger, Christoph Braüchle, Matthias P Mayer, Johannes Buchner, Rolf D Issels, Elfriede Noessner.   

Abstract

Heat shock proteins (HSPs) have shown promise for the optimization of protein-based vaccines because they can transfer exogenous antigens to dendritic cells and at the same time induce their maturation. Great care must be exercised in interpretating HSP-driven studies, as by-products linked to the recombinant generation of these proteins have been shown to mediate immunological effects. We generated highly purified human recombinant Hsp70 and demonstrated that it strongly enhances the cross-presentation of exogenous antigens resulting in better antigen-specific T cell stimulation. Augmentation of T cell stimulation was a direct function of the degree of complex formation between Hsp70 and peptides and correlated with improved antigen delivery to endosomal compartments. The Hsp70 activity was independent of TAP proteins and was not inhibited by exotoxin A or endosomal acidification. Consequently, Hsp70 enhanced cross-presentation of various antigenic sequences, even when they required different post-uptake processing and trafficking, as exemplified by the tumor antigens tyrosinase and Melan-A/MART-1. Furthermore, Hsp70 enhanced cross-presentation by different antigen-presenting cells (APCs), including dendritic cells and B cells. Importantly, enhanced cross-presentation and antigen-specific T cell activation were observed in the absence of innate signals transmitted by Hsp70. As Hsp70 supports the cross-presentation of different antigens and APCs and is inert to APC function, it may show efficacy in various settings of immune modulation, including induction of antigen-specific immunity or tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684010     DOI: 10.1074/jbc.M704129200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

Review 2.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

3.  Regulatory circuits of the AAA+ disaggregase Hsp104.

Authors:  Titus M Franzmann; Anna Czekalla; Stefan G Walter
Journal:  J Biol Chem       Date:  2011-03-23       Impact factor: 5.157

4.  Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

Authors:  Candy S Hwang; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2018-11-20       Impact factor: 3.641

Review 5.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

6.  Heat shock transcription factor 1 is activated as a consequence of lymphocyte activation and regulates a major proteostasis network in T cells critical for cell division during stress.

Authors:  Siva K Gandhapudi; Patience Murapa; Zachary D Threlkeld; Martin Ward; Kevin D Sarge; Charles Snow; Jerold G Woodward
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

7.  Inflammation-induced, 3'UTR-dependent translational inhibition of Hsp70 mRNA impairs intestinal homeostasis.

Authors:  Shien Hu; Xiaorong Zhu; Joseph R Triggs; Yun Tao; Yunwei Wang; Lev Lichtenstein; Marc Bissonnette; Mark W Musch; Eugene B Chang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

8.  Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine.

Authors:  Qiong Liu; Bo Zhai; Wen Yang; Le-Xing Yu; Wei Dong; Ya-Qin He; Lei Chen; Liang Tang; Yan Lin; Dan-Dan Huang; Hong-Ping Wu; Meng-Chao Wu; He-Xin Yan; Hong-Yang Wang
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

Review 9.  Hyperthermia as an immunotherapy strategy for cancer.

Authors:  Joseph J Skitzki; Elizabeth A Repasky; Sharon S Evans
Journal:  Curr Opin Investig Drugs       Date:  2009-06

10.  Hsp70 enhances presentation of FMDV antigen to bovine CD4+ T cells in vitro.

Authors:  Kerry McLaughlin; Julian Seago; Lucy Robinson; Charles Kelly; Bryan Charleston
Journal:  Vet Res       Date:  2010-02-02       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.